🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

P3 Health Partners appoints new CFO starting October

Published 29/08/2024, 21:18
PIII
-

HENDERSON, Nev. - P3 Health Partners Inc. (NASDAQ: PIII), a physician-led population health management company, announced the appointment of Leif Pedersen as the new Chief Financial Officer (CFO), effective October 1, 2024. Pedersen, with over 25 years of experience in finance and value-based care, will succeed Atul Kavthekar, who will transition to a Strategic Advisor role after serving as CFO until September 30, 2024.

Leif Pedersen's career includes significant roles at Optum Health and DaVita (NYSE:DVA) Medical Group, bringing a wealth of knowledge from his time in value-based care and public accounting. In his upcoming role at P3 Health Partners, Pedersen will be responsible for overseeing Accounting, Treasury, Finance Analytics, and Investor Relations.

Dr. Aric Coffman, CEO of P3 Health Partners, expressed confidence in Pedersen's ability to contribute to the company's long-term goals and uphold its commitment to value-based care. Coffman also acknowledged Kavthekar's contributions to P3 and welcomed his continued involvement as an advisor.

Pedersen shared his enthusiasm about joining P3 Health Partners, emphasizing his commitment to operational excellence and enhancing stakeholder value. He expressed eagerness to work with the P3 team towards strategic goals and to support the company's mission of delivering high-quality, cost-effective care.

P3 Health Partners, founded and led by physicians, operates an expansive network of over 2,900 affiliated primary care providers across the United States. The company focuses on supporting primary care providers with value-based care coordination and administrative services to improve patient outcomes and reduce healthcare costs.

This announcement is based on a press release statement from P3 Health Partners Inc. and contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors, many of which are beyond the company's control.

In other recent news, P3 Health Partners has reported significant changes and developments. The healthcare services company, based in Henderson, Nevada, has appointed a new Chief Financial Officer, Leif Pedersen, who will replace Atul Kavthekar effective October 1, 2024. Pedersen's compensation package includes an annual base salary of $440,000, a target annual bonus equal to 50% of his base salary, and stock options and restricted stock units totaling 1,500,000 shares of P3 Health Partners' Class A common stock.

Additionally, P3 Health Partners reported a robust 15% year-over-year revenue increase in Q2 2024, accompanied by a 6% sequential improvement in the medical cost ratio. The company has reaffirmed its full-year 2024 guidance, projecting a membership range between 125,000 and 135,000 and revenue between $1.45 billion and $1.55 billion. As part of its 2025 growth strategy, P3 Health Partners plans to increase density within existing physician markets.

The company ended Q2 2024 with $78 million in cash and a notable 50% reduction in net cash used in operating activities from the previous quarter. These recent developments reflect the company's strong financial health and its commitment to improving efficiency and performance within its existing markets.

InvestingPro Insights

As P3 Health Partners Inc. (NASDAQ: PIII) welcomes Leif Pedersen as the new CFO, investors and stakeholders may be interested in the company's financial health and market performance. According to InvestingPro data, P3 Health Partners currently has a market capitalization of approximately $177.71 million. Despite a revenue increase of 23.31% over the last twelve months as of Q2 2024, the company's gross profit margin remains low at 0.62%, reflecting some challenges in profitability.

InvestingPro Tips highlight that P3 Health Partners is trading at a low revenue valuation multiple and has been grappling with a significant stock price decline, with a 73% drop in the one-year price total return as of the most recent data. Additionally, the company does not pay a dividend to shareholders, which may be a consideration for income-focused investors. There are 8 additional InvestingPro Tips available for P3 Health Partners, offering further insights into the company's financial nuances and stock performance.

With the appointment of Pedersen, who brings extensive experience in value-based care, P3 Health Partners may be looking to address some of these financial challenges. His expertise could be pivotal in steering the company toward improved financial stability and operational excellence. As the company continues to support primary care providers and aims to reduce healthcare costs, investors will likely keep a close eye on the impact of Pedersen's financial strategies on the company's bottom line and market valuation.

For a deeper dive into P3 Health Partners' financial health and stock performance, including additional InvestingPro Tips, visit https://www.investing.com/pro/PIII.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.